Concordance of assays designed for the quantification of JAK2V617F: a multicenter study (Q39918869)

15 September 2017

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study (English)

1 reference

multicenter clinical trial

15 September 2017

0 references

author

Boris Fehse

6

1 reference

15 September 2017

N Scott Reading

5

0 references

Daniela Pietra

object named as

Daniela Pietra

15

0 references

Sian Ellard

object named as

Sian Ellard

19

0 references

Marta Sobas

16

object named as

Marta Sobas

1 reference

15 September 2017

Eric Lippert

1

1 reference

15 September 2017

François Girodon

2

1 reference

15 September 2017

Emma Hammond

3

1 reference

15 September 2017

Jaroslav Jelinek

4

1 reference

15 September 2017

Katy Hanlon

7

1 reference

15 September 2017

Mirjam Hermans

8

1 reference

15 September 2017

Céline Richard

9

1 reference

15 September 2017

Sabina Swierczek

10

1 reference

15 September 2017

Valérie Ugo

11

1 reference

15 September 2017

Serge Carillo

12

1 reference

15 September 2017

Véronique Harrivel

13

1 reference

15 September 2017

Christophe Marzac

14

1 reference

15 September 2017

Morgane Mounier

17

1 reference

15 September 2017

Marina Migeon

18

1 reference

15 September 2017

Nicolaus Kröger

20

1 reference

15 September 2017

Richard Herrmann

21

1 reference

15 September 2017

Josef T Prchal

22

1 reference

15 September 2017

Radek C Skoda

23

1 reference

15 September 2017

Sylvie Hermouet

24

1 reference

15 September 2017

10 November 2008

1 reference

15 September 2017

1 reference

15 September 2017

94

1 reference

15 September 2017

38-45

1 reference

15 September 2017

1

1 reference

Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

A gain-of-function mutation of JAK2 in myeloproliferative disorders

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Polycythemia vera is not initiated by JAK2V617F mutation.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625411

The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders

20 August 2018

1 reference

12 December 2020

Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)

1 reference

12 December 2020

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

12 December 2020

The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis

1 reference

12 December 2020

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

12 December 2020

Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis

1 reference

12 December 2020

Identifiers

DOI

10.3324/HAEMATOL.13486

1 reference

15 September 2017

1 reference

15 September 2017

1 reference